Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. (300534) Stock Analysis

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a fall in Operating Profit of -20.93%, the company declared Very Negative results in Mar 25

The company has declared negative results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Lowest at CNY 53.65 MM
NET PROFIT(HY) At CNY 25.28 MM has Grown at -31.62%
ROCE(HY) Lowest at 4.11%

With ROE of 8.04%, it has a expensive valuation with a 2.58 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 1,802 Million (Small Cap)

P/E

32.00

Industry P/E

Dividend Yield

1.01%

Debt Equity

-0.12

Return on Equity

8.04%

Price to Book

2.58

Revenue and Profits:

Net Sales:

201 Million

(Quarterly Results - Jun 2025)

Net Profit:

8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

6.01%

6 Months

-4.17%

1 Year

4.75%

2 Years

-1.86%

3 Years

-1.49%

4 Years

78.72%

5 Years

52.67%

Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

34.34%

EBIT Growth (5y)

69.83%

EBIT to Interest (avg)

19.97

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

1.36

Tax Ratio

48.75%

Dividend Payout Ratio

47.00%

Pledged Shares

Institutional Holding

ROCE (avg)

9.83%

ROE (avg)

6.21%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.58

EV to EBIT

18.14

EV to EBITDA

12.59

EV to Capital Employed

2.80

EV to Sales

1.78

PEG Ratio

Dividend Yield

1.01%

ROCE (Latest)

15.43%

ROE (Latest)

8.04%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -31.11% vs 0.21% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 35.00% vs -62.96% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "201.10",
          "val2": "291.90",
          "chgp": "-31.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "20.60",
          "val2": "26.80",
          "chgp": "-23.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "1.00",
          "chgp": "-40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "8.10",
          "val2": "6.00",
          "chgp": "35.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "53.40%",
          "val2": "64.10%",
          "chgp": "-1.07%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4.09% vs 35.17% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -38.14% vs 72.28% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,024.00",
          "val2": "1,067.70",
          "chgp": "-4.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "135.80",
          "val2": "111.90",
          "chgp": "21.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.30",
          "val2": "4.10",
          "chgp": "-19.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "51.90",
          "val2": "83.90",
          "chgp": "-38.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "95.40%",
          "val2": "76.70%",
          "chgp": "1.87%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

201.10

291.90

-31.11%

Operating Profit (PBDIT) excl Other Income

20.60

26.80

-23.13%

Interest

0.60

1.00

-40.00%

Exceptional Items

0.00

Consolidate Net Profit

8.10

6.00

35.00%

Operating Profit Margin (Excl OI)

53.40%

64.10%

-1.07%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -31.11% vs 0.21% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 35.00% vs -62.96% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,024.00

1,067.70

-4.09%

Operating Profit (PBDIT) excl Other Income

135.80

111.90

21.36%

Interest

3.30

4.10

-19.51%

Exceptional Items

-0.20

0.00

Consolidate Net Profit

51.90

83.90

-38.14%

Operating Profit Margin (Excl OI)

95.40%

76.70%

1.87%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -4.09% vs 35.17% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -38.14% vs 72.28% in Dec 2023

All Annual Results

Company CV

About Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd.

Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available